Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: Study protocol for a randomized controlled trial

Trials

Volumn 15, Issue 1, 2014, Pages

  Burtness, Barbara ^a   Bourhis, Jean P ^b   Vermorken, Jan B ^c   Harrington, Kevin J ^d,e   Cohen, Ezra E W ^f  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adjuvant; Afatinib; Head and neck; Local advanced; Phase III; Unfavourable risk

Indexed keywords

AFATINIB; CARBOPLATIN; CISPLATIN; PLACEBO;

ACNE; ADJUVANT THERAPY; ADULT; ARTICLE; CANCER RECURRENCE; CHEMORADIOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HEAD AND NECK CANCER; HIGH RISK PATIENT; HUMAN; MEDICAL HISTORY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OROPHARYNX CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SMOKING; TREATMENT DURATION; VOMITING;

EID: 84924962795     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-469     Document Type: Article

References (51)

1. GLOBOCAN: Estimated Cancer Incidence and Mortality and Prevalence Worldwide in 2012. [ http://globocan.iarc.fr ]
2. Seiwert TY, Salama JK, Vokes EE: The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 2007, 4:156-171. 10.1038/ncponc0750.
3. Argiris A, Karamouzis MV, Raben D, Ferris RL: Head and neck cancer. Lancet 2008, 371:1695-1709. 10.1016/S0140-6736(08)60728-X.
4. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002, 62:7350-7356.
5. Forastiere A, Koch W, Trotti A, Sidransky D: Head and neck cancer. N Engl J Med 2001, 345:1890-1900. 10.1056/NEJMra001375.
6. Garden AS, Harris J, Vokes EE, Forastiere AA, Ridge JA, Jones C, Horwitz EM, Glisson BS, Nabell L, Cooper JS, Demas W, Gore E: Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2004, 22:2856-2864. 10.1200/JCO.2004.12.012.
7. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000, 92:709-720. 10.1093/jnci/92.9.709.
8. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancer, Version 2.2014. [ http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf ]
9. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363:24-35. 10.1056/NEJMoa0912217.
10. Mehra R, Ang KK, Burtness B: Management of human papillomavirus-positive and human papillomavirus-negative head and neck cancer. Semin Radiat Oncol 2012, 22:194-197. 10.1016/j.semradonc.2012.03.003.
11. Broglie M, Soltermann A, Pawlita M, Huber G, Studer G, Stoeckli S: Impact of p16, p53, smoking, alcohol and staging on survival in oropharnygeal squamous cell carcinoma. In 8th International Conference on Head and Neck Cancer. Toronto, ON, Canada. 21-25 July. Los Angeles CA: The American Head & Neck Society; 2012.
12. Chung CH, Gillison ML: Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 2009, 15:6758-6762. 10.1158/1078-0432.CCR-09-0784.
13. Kreimer AR, Clifford GM, Boyle P, Franceschi S: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005, 14:467-475. 10.1158/1055-9965.EPI-04-0551.
14. Chung CH, Zhang Q, Kong C, Harris J, Ang KK, Harari PM, Wang D, Redmond KP, Shenouda G, Trotti A, Raben D, Gillison ML, Jordan R, Le QT: p16 expression as a human papillomavirus (HPV)-independent prognostic biomarker in non-oropharyngeal squamous cell carcinoma (non-OPSCC). ASCO Meeting Abstracts 2013,31(Suppl 15):6007.
15. Rischin D, Young RJ, Fisher R, Fox SB, Le QT, Peters LJ, Solomon B, Choi J, O'Sullivan B, Kenny LM, McArthur GA: Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010, 28:4142-4148. 10.1200/JCO.2010.29.2904.
16. Young RJ, Rischin D, Fisher R, McArthur GA, Fox SB, Peters LJ, Corry J, Lim A, Waldeck K, Solomon B: Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2011, 20:1230-1237. 10.1158/1055-9965.EPI-10-1262.
17. Pignon JP, Le Maitre A, Maillard E, Bourhis J: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92:4-14. 10.1016/j.radonc.2009.04.014.
18. Jacobs C, Makuch R: Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: a subset analysis of the head and neck contracts program. J Clin Oncol 1990, 8:838-847.
19. Laramore GE, Scott CB, Al-Sarraf M, Haselow RE, Ervin TJ, Wheeler R, Jacobs JR, Schuller DE, Gahbauer RA, Schwade JG: Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys 1992, 23:705-713. 10.1016/0360-3016(92)90642-U.
20. Armand JP, Couteau C: Chemotherapy in head and neck cancer. Eur J Cancer 1995, 31A:819-822.
21. Stell PM, Rawson NS: Adjuvant chemotherapy in head and neck cancer. Br J Cancer 1990, 61:779-787. 10.1038/bjc.1990.175.
22. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366:2-16. 10.1016/j.gene.2005.10.018.
23. Agulnik M: New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Med Oncol 2012, 29:2481-2491. 10.1007/s12032-012-0159-2.
24. Pectasides E, Rampias T, Kountourakis P, Sasaki C, Kowalski D, Fountzilas G, Zaramboukas T, Rimm D, Burtness B, Psyrri A: Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma. Clin Cancer Res 2011, 17:2947-2954. 10.1158/1078-0432.CCR-10-2040.
25. Bristol-Myers Squibb/Eli Lilly: Erbitux® (Cetuximab) Prescribing Information. [ http://packageinserts.bms.com/pi/pi_erbitux.pdf ]
26. Merck Serono: Erbitux 5 mg/ml Solution for Infusion - Summary of Product Characteristics. [ http://www.medicines.org.uk/emc/medicine/19595 ]
27. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578. 10.1056/NEJMoa053422.
28. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005, 23:8646-8654. 10.1200/JCO.2005.02.4646.
29. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359:1116-1127. 10.1056/NEJMoa0802656.
30. Rogers SJ, Harrington KJ, Rhys-Evans P, Charoenrat P, Eccles SA: Biological significance of c-ErbB family oncogenes in head and neck cancer. Cancer Metastasis Rev 2005, 24:47-69. 10.1007/s10555-005-5047-1.
31. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM: Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008, 27:3944-3956. 10.1038/onc.2008.19.
32. GlaxoSmithKline: Study of adjuvant lapatinib in high-risk head and neck cancer subjects after surgery. [ http://clinicaltrials.gov/ct2/show/NCT00424255 ]
33. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27:4702-4711. 10.1038/onc.2008.109.
34. Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR: Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012, 343:342-350. 10.1124/jpet.112.197756.
35. Food and Drug Administration: Gilotrif Prescribing Information. [ http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/201292s000lbl.pdf ]
36. European Medicines Agency: Gilotrif - European Public Assessment Report. [ http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002280/human_med_001698.jsp&mid=WC0b01ac058001d124 ]
37. Pharmaceuticals and Medical Devices Agency Japan: New drugs approved in FY 2013. [ http://www.pmda.go.jp/english/service/pdf/list/NewdrugsFY2013.pdf ]
38. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3327-3334. 10.1200/JCO.2012.44.2806.
39. Yang JC-H, Sequist LV, Schuler MH, Mok T, Yamamoto N, O'Byrne KJ, Hirsh V, Geater SL, Zhou C, Massey D, Zazulina V, Wu Y-L: Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) [abstract]. J Clin Oncol 2014,32(15s):8004.
40. Schutze C, Dorfler A, Eicheler W, Zips D, Hering S, Solca F, Baumann M, Krause M: Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther Onkol 2007, 183:256-264. 10.1007/s00066-007-1696-z.
41. Solca F, Baum A, Krause M, Baumann M, Wong K, Greulich H, Guenther A: Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2, in models of head and neck cancer. Eur J Cancer Suppl 2007, 5:326-327.
42. Seiwert TY, Fayette J, Cupissol D, Del Campo JM, Clement PM, Hitt R, Degardin M, Zhang W, Blackman A, Ehrnrooth E, Cohen EE: A randomized, phase 2 study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 2014, 25:1813-1820. 10.1093/annonc/mdu216.
43. Lacouture ME, Schadendorf D, Chu CY, Uttenreuther-Fischer M, Stammberger U, O'Brien D, Hauschild A: Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther 2013, 13:721-728. 10.1586/era.13.30.
44. Yang JC, Reguart N, Barinoff J, Kohler J, Uttenreuther-Fischer M, Stammberger U, O'Brien D, Wolf J, Cohen EE: Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther 2013, 13:729-736. 10.1586/era.13.31.
45. Eskens FA, Mom CH, Planting AS, Gietema JA, Amelsberg A, Huisman H, van Doorn L, Burger H, Stopfer P, Verweij J, de Vries EG: A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 2008, 98:80-85. 10.1038/sj.bjc.6604108.
46. Gordon MS, Mendelson DS, Gross M, Uttenreuther-Fischer M, Ould-Kaci M, Zhao Y, Stopfer P, Agus DB: A phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs 2013, 31:409-416. 10.1007/s10637-012-9904-9.
47. Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA: Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012, 13:539-548. 10.1016/S1470-2045(12)70086-4.
48. Wu YL, Zhou C, Hu CP, Feng JF, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Massey D, Shi Y, Chen J, Zazulina V, Geater SL: LUX-Lung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung [abstract]. J Clin Oncol 2013,31(15s):8016.
49. Langer CJ: Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer? J Clin Oncol 2013, 31:3303-3306. 10.1200/JCO.2013.49.8782.
50. Machiels JP, Licitra LF, Haddad RI, Tahara M, Cohen EE: Rationale and design of LUX-Head & Neck 1: a randomised. Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. BMC Cancer 2014, 14:473. 10.1186/1471-2407-14-473.
51. Machiels J, Haddad R, Fayette J, Licitra L, Tahara M, Vermorken J, Clement P, Gauler T, Cupissol D, Grau J, Guigay J, Caponigro F, De Castro JG, De Souza VL, Keilholz U, Del Campo J, Cong X, Svensson L, Ehrnrooth E, Cohen E: Afatinib versus methotrexate (MTX) as second-line treatment for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy: primary efficacy results of LUX-Head & Neck 1, a phase III trial [abstract]. Ann Onc 2014, 25:S4.